Pilot corpus: NIH-funded biomedical datasets. Any DOI can be scored on demand — network effects sharpen as coverage grows.

Mutant KRAS peptide targeted CAR-T cells engineered for cancer therapy

Cancer Cell(2025)10.1016/j.ccell.2025.05.006Source: DataRank Database

Mutant KRAS peptide targeted CAR-T cells engineered for cancer therapy is a research paper published in Cancer Cell (2025). On theSindex it has a DataRank of 0. It has been cited 28 times.

N/A

0DataRank · unranked

Scored on demand from live citation data

Open Access28 citations

Download PDF

Cite:

Linked data & code

cellosaurus

DataRank reads this dataset's downstream impact straight off the citation graph — no black box, no proprietary weighting. How is this computed?

›Methodology & internals

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Pipeline:MetadataData-paper checkEnrichmentCitation networkScoring

Enrichment:Funding (10 grants)Impact (FWCI 14.14)OA: greenTopics (40)IDs (PubMed, PMC, OpenAlex)Annotations (1)SDGs (1)

FAIR Checklist

Context only (not used in score)

Findable (1/2)

Has DOI

Accessible (1/2)

Open Access

Interoperable (0/2)

Reusable (0/3)

FAIR checklist signals are shown for context only and do not affect DataRank scoring.

Run a calibrated FAIR evaluation for this paper →

We only score data papers we can read in full — never from an abstract alone.

Authors (12)

Jia‐Geng Liu ORCID,Mathilde Poussin ORCID,Andrea Lang Goldgewicht ORCID,Madhara Udawela ORCID,Adham S. Bear ORCID

Live enrichment

PubMed:40480232 PMC:PMC12263316 OpenAlex:https://openalex.org/W4411059516

Lustgarten Foundation

Grant: SUC-AACR-PCC-07-18

University of Pennsylvania

Grant: R01CA260902

University of Pennsylvania

Grant: R01EB026892

National Science Foundation

Grant: DGE-2236662

NIGMS NIH HHS

Grant: T32 GM008076

National Institutes of Health

National Institute of Biomedical Imaging and Bioengineering

National Institutes of Health National Cancer Institute

Stand Up To Cancer

Blavatnik Family Foundation

FWCI

14.14

Citation Percentile

1.0%

Citation Trend

2025

2026

greenLicense: http://www.elsevier.com/open-access/userlicense/1.0/

repositoryhttps://pmc.ncbi.nlm.nih.gov/articles/PMC12263316/

publisherhttps://api.elsevier.com/content/article/PII:S1535610825002156?httpAccept=text/xml

publisherhttps://api.elsevier.com/content/article/PII:S1535610825002156?httpAccept=text/plain

journalhttps://doi.org/10.1016/j.ccell.2025.05.006

Fields of Study

CAR-T cell therapy researchNanowire Synthesis and ApplicationsViral Infectious Diseases and Gene Expression in Insects

MeSH Terms

Receptors, Chimeric AntigenAnimalsHumansLung NeoplasmsMutationNeoplasmsPeptidesReceptors, Antigen, T-CellT-LymphocytesImmunotherapy, AdoptiveProto-Oncogene Proteins p21(ras)Xenograft Model Antitumor AssaysCell Line, TumorMice

Keywords

KRASMutantPeptideCancerCancer researchCancer cellTargeted therapyCancer therapyMutationBiologyColorectal cancerGeneticsGeneBiochemistryIL-12T cellSolid TumorsCrisprCartCellular ImmunotherapyTherapeutic IndexNeo-antigenArmored Car

Sustainable Development Goals

SDG 0: Good health and well-being

Mutant KRAS peptide targeted CAR-T cells engineered for cancer therapy

FAIR Checklist

Authors (12)

Funding (10 grants)

Impact

Open Access

Topics

Annotations (Europe PMC)